Giuseppe di Salvo - 01 Jun 2026 Form 3 Insider Report for AVIENT CORP (AVNT)

Reporting relationship: SVP, Chief Financial Officer
Issuer ticker: AVNT
Reported as of: 01 Jun 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 01 Jun 2026, 16:51:51 UTC
Source filing: View source filing
Reporting owner signature: /s/ Robert K. James, Power of Attorney for Giuseppe Di Salvo

Key filing fact

Giuseppe di Salvo filed Form 3 for AVIENT CORP (AVNT) on 01 Jun 2026.

Key facts

This page summarizes Giuseppe di Salvo's Form 3 filing for AVIENT CORP (AVNT).
0 reported transactions and 9 derivative rows are listed below.
Accepted by SEC: 01 Jun 2026, 16:51.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002132871 Primary reporting owner

Di Salvo Giuseppe

Relationship: SVP, Chief Financial Officer
Address: AVIENT CORPORATION, 33587 WALKER ROAD, AVON LAKE
Signature: /s/ Robert K. James, Power of Attorney for Giuseppe Di Salvo
Signature date: 01 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVNT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 18,300
Date: 01 Jun 2026
Ownership: Supplemental Plan
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVNT holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,761
Exercise price
Footnotes: F2, F3

AVNT holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,179
Exercise price
Footnotes: F3, F4

AVNT holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,783
Exercise price
Footnotes: F3, F5

AVNT holding Derivative

Stock Appreciation Rights

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,637
Exercise price: $31.54
Footnotes: F6

AVNT holding Derivative

Stock Appreciation Rights

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,713
Exercise price: $31.48
Footnotes: F7

AVNT holding Derivative

Stock Appreciation Rights

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,470
Exercise price: $42.27
Footnotes: F8

AVNT holding Derivative

Stock Appreciation Rights

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,250
Exercise price: $52.64
Footnotes: F9

AVNT holding Derivative

Stock Appreciation Rights

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $42.93
Footnotes: F10

AVNT holding Derivative

Stock Appreciation Rights

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,250
Exercise price: $39.27
Footnotes: F11

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 11 footnotes

Footnote F1

The information in this report is based on a plan statement as of June 1, 2026.

Footnote F2

The restricted stock units vest 3 years from the date of grant on February 22, 2027.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of Avient common stock.

Footnote F4

The restricted stock units vest in substantially equal installments on each of February 19, 2027 and February 19, 2028, unless earlier vested or terminated pursuant to the terms of the grant agreement.

Footnote F5

The restricted stock units vest in substantially equal installments on each of February 20, 2027, February 20, 2028 and February 20, 2029, unless earlier vested or terminated pursuant to the terms of the grant agreement.

Footnote F6

Stock appreciation rights ("SARs") become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of thirty consecutive trading days) from the grant date closing price of $31.54 per share and no more than one-third of the grant can vest per year during the first three years.

Footnote F7

SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of thirty consecutive trading days) from the grant date closing price of $31.48 per share and no more than one-third of the grant can vest per year during the first three years.

Footnote F8

SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of thirty consecutive trading days) from the grant date closing price of $42.27 per share and no more than one-third of the grant can vest per year during the first three years

Footnote F9

SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of thirty consecutive trading days) from the grant date closing price of $52.64 per share and no more than one-third of the grant can vest per year during the first three years.

Footnote F10

SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of twenty consecutive trading days) from the grant date closing price of $42.93 per share and no more than one-third of the grant can vest per year during the first three years.

Footnote F11

SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of twenty consecutive trading days) from the grant date closing price of $39.27 per share and no more than one-third of the grant can vest per year during the first three years.

SEC remarks

Exhibit 24.1 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .